作者：
Shuo,Feng [1]
;
Daniel J,Phillips [1]
;
Thomas,White [2]
;
Homesh,Sayal [2]
;
Parvinder K,Aley [1]
;
Sagida,Bibi [1]
;
Christina,Dold [1]
;
Michelle,Fuskova [3]
;
Sarah C,Gilbert [3]
;
Ian,Hirsch [2]
;
Holly E,Humphries [4]
;
Brett,Jepson [5]
;
Elizabeth J,Kelly [6]
;
Emma,Plested [7]
;
Kathryn,Shoemaker [1]
;
Kelly M,Thomas [5]
;
Johan,Vekemans [4]
;
Tonya L,Villafana [8]
;
Teresa,Lambe [5]
;
Andrew J,Pollard [3]
;
Merryn,Voysey [9]
;
Oxford COVID Vaccine Trial Group [1]
作者单位：
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
[1]
Late-stage development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
[2]
The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
[3]
National Infection Service, Public Health England, Salisbury, UK.
[4]
Late-stage development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
[5]
Cytel Inc., Cambridge, MA, USA.
[6]
Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
[7]
Late-stage development Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
[8]
Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
[9]
NIHR Oxford Biomedical Centre, Oxford, UK.
[10]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. merryn.voysey@paediatrics.ox.ac.uk.
[11]
NIHR Oxford Biomedical Centre, Oxford, UK. merryn.voysey@paediatrics.ox.ac.uk.
[12]
主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 中和(Antibodies, Neutralizing);抗体, 病毒(Antibodies, Viral);无症状感染(Asymptomatic Infections);队列研究(Cohort Studies);女(雌)性(Female);人类(Humans);免疫, 体液(Immunity, Humoral);免疫接种, 加强(Immunization, Secondary);感染控制(Infection Control);男(雄)性(Male);中年人(Middle Aged);治疗结果(Treatment Outcome);接种(Vaccination);青年人(Young Adult)
DOI
10.1038/s41591-021-01540-1
PMID
34588689
发布时间
2024-02-21
换一批
换一批
